Cargando…

Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study

INTRODUCTION: Tissue inhibitor of metalloproteinase-2 (TIMP-2) is an emerging acute kidney injury (AKI) biomarker. We evaluated the performance of urinary TIMP-2 in an adult mixed ICU by comparison with other biomarkers that reflect several different pathways of AKI. METHODS: In this study, we prosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamashita, Tetsushi, Doi, Kent, Hamasaki, Yoshifumi, Matsubara, Takehiro, Ishii, Takeshi, Yahagi, Naoki, Nangaku, Masaomi, Noiri, Eisei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300076/
https://www.ncbi.nlm.nih.gov/pubmed/25524453
http://dx.doi.org/10.1186/s13054-014-0716-5
_version_ 1782353478065061888
author Yamashita, Tetsushi
Doi, Kent
Hamasaki, Yoshifumi
Matsubara, Takehiro
Ishii, Takeshi
Yahagi, Naoki
Nangaku, Masaomi
Noiri, Eisei
author_facet Yamashita, Tetsushi
Doi, Kent
Hamasaki, Yoshifumi
Matsubara, Takehiro
Ishii, Takeshi
Yahagi, Naoki
Nangaku, Masaomi
Noiri, Eisei
author_sort Yamashita, Tetsushi
collection PubMed
description INTRODUCTION: Tissue inhibitor of metalloproteinase-2 (TIMP-2) is an emerging acute kidney injury (AKI) biomarker. We evaluated the performance of urinary TIMP-2 in an adult mixed ICU by comparison with other biomarkers that reflect several different pathways of AKI. METHODS: In this study, we prospectively enrolled 98 adult critically ill patients who had been admitted to the adult mixed ICU. Urinary TIMP-2 and N-acetyl-β-d-glucosaminidase (NAG) and plasma neutrophil gelatinase-associated lipocalin (NGAL), interleukin-6 (IL-6) and erythropoietin (EPO) were measured on ICU admission. We evaluated these biomarkers’ capability of detecting AKI and its severity as determined by using the Kidney Disease Improving Global Outcomes serum creatinine criteria, as well as its capacity to predict in-hospital mortality. The impact of sepsis, the leading cause of AKI in ICUs, was also evaluated. RESULTS: We found AKI in 42 patients (42.9%). All biomarkers were significantly higher in AKI than in non-AKI. In total, 27 patients (27.6%) developed severe AKI. Urinary TIMP-2 was able to distinguish severe AKI from non-severe AKI with an area under the receiver operating characteristic curve (AUC-ROC) of 0.80 (95% confidence interval, 0.66 to 0.90). A total of 41 cases (41.8%) were complicated with sepsis. Although plasma NGAL and IL-6 were increased by sepsis, urinary TIMP-2 and NAG were increased not by sepsis, but by the presence of severe AKI. Plasma EPO was increased only by septic AKI. In-hospital mortality was 15.3% in this cohort. Urinary TIMP-2 and NAG, and plasma NGAL, were significantly higher in non-survivors than in survivors, although plasma IL-6 and EPO were not. Among the biomarkers, only urinary TIMP-2 was able to predict in-hospital mortality significantly better than serum creatinine. CONCLUSION: Urinary TIMP-2 can detect severe AKI with performance equivalent to plasma NGAL and urinary NAG, with an AUC-ROC value higher than 0.80. Furthermore, urinary TIMP-2 was associated with mortality. Sepsis appeared to have only a limited impact on urinary TIMP-2, in contrast to plasma NGAL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-014-0716-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4300076
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43000762015-01-21 Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study Yamashita, Tetsushi Doi, Kent Hamasaki, Yoshifumi Matsubara, Takehiro Ishii, Takeshi Yahagi, Naoki Nangaku, Masaomi Noiri, Eisei Crit Care Research INTRODUCTION: Tissue inhibitor of metalloproteinase-2 (TIMP-2) is an emerging acute kidney injury (AKI) biomarker. We evaluated the performance of urinary TIMP-2 in an adult mixed ICU by comparison with other biomarkers that reflect several different pathways of AKI. METHODS: In this study, we prospectively enrolled 98 adult critically ill patients who had been admitted to the adult mixed ICU. Urinary TIMP-2 and N-acetyl-β-d-glucosaminidase (NAG) and plasma neutrophil gelatinase-associated lipocalin (NGAL), interleukin-6 (IL-6) and erythropoietin (EPO) were measured on ICU admission. We evaluated these biomarkers’ capability of detecting AKI and its severity as determined by using the Kidney Disease Improving Global Outcomes serum creatinine criteria, as well as its capacity to predict in-hospital mortality. The impact of sepsis, the leading cause of AKI in ICUs, was also evaluated. RESULTS: We found AKI in 42 patients (42.9%). All biomarkers were significantly higher in AKI than in non-AKI. In total, 27 patients (27.6%) developed severe AKI. Urinary TIMP-2 was able to distinguish severe AKI from non-severe AKI with an area under the receiver operating characteristic curve (AUC-ROC) of 0.80 (95% confidence interval, 0.66 to 0.90). A total of 41 cases (41.8%) were complicated with sepsis. Although plasma NGAL and IL-6 were increased by sepsis, urinary TIMP-2 and NAG were increased not by sepsis, but by the presence of severe AKI. Plasma EPO was increased only by septic AKI. In-hospital mortality was 15.3% in this cohort. Urinary TIMP-2 and NAG, and plasma NGAL, were significantly higher in non-survivors than in survivors, although plasma IL-6 and EPO were not. Among the biomarkers, only urinary TIMP-2 was able to predict in-hospital mortality significantly better than serum creatinine. CONCLUSION: Urinary TIMP-2 can detect severe AKI with performance equivalent to plasma NGAL and urinary NAG, with an AUC-ROC value higher than 0.80. Furthermore, urinary TIMP-2 was associated with mortality. Sepsis appeared to have only a limited impact on urinary TIMP-2, in contrast to plasma NGAL. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13054-014-0716-5) contains supplementary material, which is available to authorized users. BioMed Central 2014-12-19 2014 /pmc/articles/PMC4300076/ /pubmed/25524453 http://dx.doi.org/10.1186/s13054-014-0716-5 Text en © Yamashita et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Yamashita, Tetsushi
Doi, Kent
Hamasaki, Yoshifumi
Matsubara, Takehiro
Ishii, Takeshi
Yahagi, Naoki
Nangaku, Masaomi
Noiri, Eisei
Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study
title Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study
title_full Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study
title_fullStr Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study
title_full_unstemmed Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study
title_short Evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study
title_sort evaluation of urinary tissue inhibitor of metalloproteinase-2 in acute kidney injury: a prospective observational study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4300076/
https://www.ncbi.nlm.nih.gov/pubmed/25524453
http://dx.doi.org/10.1186/s13054-014-0716-5
work_keys_str_mv AT yamashitatetsushi evaluationofurinarytissueinhibitorofmetalloproteinase2inacutekidneyinjuryaprospectiveobservationalstudy
AT doikent evaluationofurinarytissueinhibitorofmetalloproteinase2inacutekidneyinjuryaprospectiveobservationalstudy
AT hamasakiyoshifumi evaluationofurinarytissueinhibitorofmetalloproteinase2inacutekidneyinjuryaprospectiveobservationalstudy
AT matsubaratakehiro evaluationofurinarytissueinhibitorofmetalloproteinase2inacutekidneyinjuryaprospectiveobservationalstudy
AT ishiitakeshi evaluationofurinarytissueinhibitorofmetalloproteinase2inacutekidneyinjuryaprospectiveobservationalstudy
AT yahaginaoki evaluationofurinarytissueinhibitorofmetalloproteinase2inacutekidneyinjuryaprospectiveobservationalstudy
AT nangakumasaomi evaluationofurinarytissueinhibitorofmetalloproteinase2inacutekidneyinjuryaprospectiveobservationalstudy
AT noirieisei evaluationofurinarytissueinhibitorofmetalloproteinase2inacutekidneyinjuryaprospectiveobservationalstudy